Physician profile
Anamaria M Manea
NPI 1770843856
$23,336.17
in general payments reported to CMS, 2019-2025
12 companies · $22K in 2025
The $22K reported for 2025 was more than what 93% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $24.38 · 2022: $134 · 2023: $137 · 2024: $965 · 2025: $22K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,975 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,595 · Travel and Lodging: $1,657 · Food and Beverage: $1,629 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,975.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,595.00 |
| Travel and Lodging | $1,657.12 |
| Food and Beverage | $1,629.28 |
| Education | $149.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $13,315.41 | 2025 | |
| Kyowa Kirin, INC. | $7,325.46 | 2025 | |
| Eton Pharmaceuticals, INC. | $1,000.00 | 2025 | Alkindi, Increlex, Khindivi |
| Astrazeneca Pharmaceuticals Lp | $725.00 | 2024 | Strensiq |
| Alexion Pharmaceuticals, INC. | $171.28 | 2019 | |
| Insulet Corporation | $137.57 | 2025 | Omnipod |
| Sanofi-Aventis U.S. LLC | $137.50 | 2024-2025 | |
| Ascensia Diabetes Care US INC. | $137.49 | 2023 | |
| Abbott Laboratories | $134.34 | 2022 | |
| Novo Nordisk INC | $133.51 | 2024 | Sogroya |
| Ascendis Pharma Endocrinology INC | $94.23 | 2025 | Yorvipath, Skytrofa |
| Companion Medical, INC. | $24.38 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anamaria Manea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.